Antiangiogenic therapeutic approaches in multiple myeloma.
Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. The pathophysiology of MM-induced angiogenesis involves both direct production of angiogenic cytokines by plasma cells and their induction within the bone marrow microenvironment. An improved understanding of the importance of angiogenesis-related signaling in MM has allowed for the rational use of antiangiogenic therapies in this tumor. This review article summarizes the literature data concerning the employment of the most important antiangiogenic therapeutic agents actually used in preclinical models and clinical settings for the treatment of MM.
Department of Basic Medical Sciences, Section of Human Anatomy and Histology, University of Bari Medical School, Piazza Giulio Cesare, 11, Bari, Italy. ribatti@anatomia.uniba.it
Domenico
D
Ribatti
Giuseppe
G
Mangialardi
Angelo
A
Vacca
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009101:Multiple Myeloma / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic
D020533:Angiogenesis Inhibitors